A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05873686 |
Recruitment Status :
Recruiting
First Posted : May 24, 2023
Last Update Posted : February 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumor | Drug: NXP900 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Sequential assignment, dose escalation |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers |
Actual Study Start Date : | October 26, 2023 |
Estimated Primary Completion Date : | September 2024 |
Estimated Study Completion Date : | January 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation
Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day.
|
Drug: NXP900
NXP900 is an orally administered SRC/YES1 kinase inhibitor |
- Number of patients with treatment related adverse events and/or clinical laboratory abnormalities [ Time Frame: Day 28 ]
- Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol [ Time Frame: Day 28 ]
- Area under the concentration-time curve (AUC) of NXP900 [ Time Frame: First dose through Day 29 ]
- Maximum observed concentration (Cmax) of NXP900 [ Time Frame: First dose through Day 29 ]
- Time to peak concentration (Tmax) of NXP900 [ Time Frame: First dose through Day 29 ]
- Half-life (T1/2) of NXP900 [ Time Frame: First dose through Day 29 ]
- Apparent volume of distribution at steady state (Vss/F) of NXP900 [ Time Frame: First dose through Day 29 ]
- Apparent plasma clearance at steady state (Clss/F) of NXP900 [ Time Frame: First dose through Day 29 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Provide written informed consent.
- 18 years old or older.
- Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Exclusion Criteria:
- Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.
- Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
- Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy.
- Subjects with treated brain metastases with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
- Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
- Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
- Major surgery from which the subject has not yet recovered.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05873686
Contact: Diane Marsolini | (201) 627-8154 | dmarsolini@nuvectis.com | |
Contact: Shay Shemesh | (201) 614-3153 | sshemesh@nuvectis.com |
United States, Colorado | |
Sarah Cannon Research Institute at HealthONE | Recruiting |
Denver, Colorado, United States, 80218 | |
Contact 720-754-2610 | |
United States, Oregon | |
Oregon Health and Science University | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact 503-494-6865 | |
United States, Texas | |
The University of Texas MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Jordi Rodon Ahnert, MD, PhD 713-792-5603 | |
United Kingdom | |
The Royal Marsden NHS Foundation and Trust | Recruiting |
London, United Kingdom, SW3 6JJ |
Principal Investigator: | Udai Banerji, Prof | Institute of Cancer Research, Royal Marsden NHS Foundation Trust |
Responsible Party: | Nuvectis Pharma, Inc. |
ClinicalTrials.gov Identifier: | NCT05873686 |
Other Study ID Numbers: |
NXP900-101 |
First Posted: | May 24, 2023 Key Record Dates |
Last Update Posted: | February 6, 2024 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Solid Tumor Carcinoma Neoplasms Adenocarcinoma |